 VBI Vaccines will find out on November 30th whether its Hepatitis B vaccine - already approved in Israel - will be approved by the FDA in the US. Approval in the US - and Europe, where a marketing authorization is also being sought - could be a potential game-changer for the company, although this is a tricky market. 